Time for Action to Curb Resistance

The research-based biopharmaceutical industry at the forefront of addressing antimicrobial resistance (AMR)

Joining forces to beat superbugs

In January 2016, together with the generics and diagnostics industries, we launched a joint Declaration to call for collective action from governments and relevant stakeholders against the spread of drug-resistant infections. The Declaration sets out a common set of principles for global action to support antibiotic conservation and the development of new drugs, diagnostics and vaccines. The Declaration is twofold:

A call to action for governments

We call on governments to go beyond existing statements of intent and take concrete action, in collaboration with companies, to support investment in the development of antibiotics, diagnostics, and vaccines. New and alternative market structures that provide more dependable and sustainable market models for antibiotics are needed to provide appropriate incentives for companies to invest in R&D and overcome the formidable technical and scientific challenges of antibiotic discovery and development.

A series of commitments from companies

We set out commitments for further action on drug resistance across three areas:

1. Work to reduce the development of antimicrobial resistance

2. Invest in R&D that meets global public health needs with new innovative diagnostics and treatments

3. Improve access to high-quality antibiotics and ensuring that new ones are available to all

Delivering on the Industry Declaration

Our programs support the efforts made to meet preservation goals, incentivize innovation and ensure sustainable antibiotic treatments are available to address the health challenges of the future.

Jacqueline 6/17/2021

<table>
<thead>
<tr>
<th>1. Work to reduce the development of antimicrobial resistance</th>
<th>2. Invest in R&amp;D that meets global public health needs with new innovative diagnostics and treatments</th>
<th>3. Improve access to high-quality antibiotics and ensuring that new ones are available to all</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support appropriate use and improved stewardship</td>
<td>Invest in innovative antibiotics, vaccines, alternative technologies, and diagnostics</td>
<td>Ensure affordable access to new and existing antibiotics</td>
</tr>
<tr>
<td>Encourage infection control</td>
<td>Support research in academia and Small and Medium Enterprises on new and re-purposed antibiotics</td>
<td>Support programs to improve global access</td>
</tr>
<tr>
<td>Support the one health approach and responsible use</td>
<td>Support open collaboration between industry and public researchers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Develop new valuation mechanisms and commercial models with payers and policy makers</td>
<td></td>
</tr>
</tbody>
</table>

Check out [www.partnerships.ifpma.org](http://www.partnerships.ifpma.org) for insights into collaborative initiatives to combat antimicrobial resistance (AMR). In just a few clicks you can find relevant programs, identify who are the key players, determine where and how they operate, and find out how they are making a difference.